This study establishes a new protocol that will improve the ability of TGF-β to induce iTreg cells ex vivo, thereby increasing the likelihood that manipulation of TGF-β-induced iTreg cells may provide a novel therapeutic strategy for the treatment of autoimmune diseases and other chronic inflammatory diseases. The gene discussed is TGFB1; the disease is autoimmune disease.